Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.34 |
| ▸ | CA1 | P00915 | 9/20 | 0.34 |
| ▸ | CA9 | Q16790 | 6/20 | 0.33 |
| ▸ | CA12 | O43570 | 6/20 | 0.33 |
| ▸ | CA4 | P22748 | 5/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.33 |
| ▸ | CA7 | P43166 | 4/20 | 0.33 |
| ▸ | CA6 | P23280 | 3/20 | 0.33 |
| ▸ | CA5A | P35218 | 3/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465074 | 0.81 | CA2 (0.32) | CA2CA1CA9CA12CA4 | |
| SCHEMBL3465533 | 0.78 | CA2 (0.32) | CA2CA1CA9CA12CA4 | |
| SCHEMBL28771443 | 0.77 | CA1 (0.31) | CA2CA1CA9CA12CA4 | |
| SCHEMBL29037007 | 0.76 | CA1 (0.32) | CA2CA1CA9MAPK1 | |
| SCHEMBL6449500 | 0.74 | SLC40A1 (0.47) | CA2CA1CA9CA12CA4 | |
| SCHEMBL9376282 | 0.73 | KCNH2 (0.42) | CA2CA1CA9CA12CA4 | |
| SCHEMBL3466761 | 0.73 | PIM1 (0.34) | CA2CA1CA9CA12CA4 | |
| SCHEMBL17647899 | 0.71 | NOS3 (0.43) | CA2CA1CA9CA12CA4 | |
| SCHEMBL6501463 | 0.69 | CYP3A4 (0.43) | CA2CA1CA9CA12CA4 | |
| SCHEMBL9376409 | 0.69 | CA2 (0.38) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | CA2 2686/4885CA1 1081/4885CA9 1728/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | CA2 3968/4885CA1 2206/4885CA9 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.